SLNO Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages SLNO Investors with Losses to Contact the Firm

Affected Soleno Therapeutics, Inc. Investor Summary

• Who: Soleno Therapeutics, Inc. (NASDAQ: SLNO)
• What: Securities fraud class action lawsuit filed
• Class Period: March 26, 2025, through November 4, 2025
• Deadline to Seek Lead Plaintiff Status: May 5, 2026
• Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's Phase 3 clinical trial program for diazoxide choline extended-release tablets ("DCCR").  
• Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options at no cost to investor

RADNOR, Pa., March 26, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO) on behalf of those who purchased or acquired Soleno common stock between March 26, 2025, and November 4, 2025, inclusive. The lawsuit is filed in the United States District Court for the Northern District of California and is captioned City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., et al, Case No. 3:26-cv-01979 (N.D. Cal.).  Investors have until May 5, 2026, to file for lead plaintiff status.